Oppenheimer Downgrades Aerovate(AVTE.US) to Hold Rating, Cuts Target Price to $3
Analysts Conflicted on These Healthcare Names: Oric Pharmaceuticals (ORIC), Aerovate Therapeutics (AVTE) and McKesson (MCK)
Aerovate Therapeutics Analyst Ratings
Wedbush Downgrades Aerovate Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $41
Aerovate Therapeutics Analyst Ratings
Jefferies Sticks to Its Buy Rating for Aerovate Therapeutics (AVTE)
Aerovate Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Aerovate Therapeutics (AVTE)
Aerovate Therapeutics Analyst Ratings
Wedbush Remains a Buy on Aerovate Therapeutics (AVTE)
Aerovate Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Aerovate Therapeutics (AVTE) and Delcath Systems (DCTH)
Aerovate Therapeutics Analyst Ratings
TD Cowen Sticks to Its Buy Rating for Aerovate Therapeutics (AVTE)
Aerovate Therapeutics (AVTE) Receives a Buy From BTIG
Buy Rating Affirmed: Aerovate Therapeutics' AV-101 Shows Strong Potential Amid Successful IMPAHCT Trial Progression
Analysts' Top Healthcare Picks: Aerovate Therapeutics (AVTE), Calidi Biotherapeutics (CLDI)
Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET) and Aerovate Therapeutics (AVTE)
TD Cowen Sticks to Their Buy Rating for Aerovate Therapeutics (AVTE)
Wedbush Adjusts Aerovate Therapeutics Price Target to $48 From $50, Maintains Outperform Rating